Our hunger to keep progressing, and to deliver what patients need from science, keeps us focused on what matters. We embrace the challenge in science.
Detail of a production phase in Dompé farmaceutici.
The Curiositas that inspired Leonardo da Vinci to imagine inventions ahead of his time, remains a stimulus for those doing scientific research today. It is by drawing inspiration from his tireless drive to know and improve that Dompè came to support the Confindustria project.
Research and the courage to experiment, even at the risk of failure, are what has guided us for more than a century to engage in Life Sciences to improve people’s lives.
It is precisely this focus that has led us to invest in artificial intelligence and supercomputing and to turn the Nerve Growth Factor, discovered by Nobel laureates in medicine Rita Levi Montalcini and Stanley Cohen, into a “breakthrough” drug for the treatment of a rare and orphan disease.
Detail of the virtual environment of Exscalate, the most advanced intelligent supercomputing platform for the screening of new drugs developed by Dompé farmaceutici.
Researchers at work in the laboratory.
Aerial view of the Dompé pharmaceutical plant in L'Aquila.
Dompé is a private, rapidly scaling global biopharmaceutical company founded in Milan, Italy, with a 130-year legacy of medical innovation. The R&D department of the company is anchored by EXSCALATE, a structure-based virtual screening platform developed in-house that leverages one of the most powerful supercomputing and artificial intelligence platforms in the world. Today, Dompé employs more than 800 employees worldwide and maintains a U.S. commercial operations hub in the San Francisco Bay Area as well as an R&D presence in Boston.
